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Epigenome-wide association study of
metabolic syndrome in African-American
adults
Tomi Akinyemiju1*, Anh N. Do2, Amit Patki3, Stella Aslibekyan2, Degui Zhi4,5, Bertha Hidalgo2, Hemant K. Tiwari3,
Devin Absher6, Xin Geng4, Donna K. Arnett7 and Marguerite R. Irvin2
Abstract
Background: The high prevalence of obesity among US adults has resulted in significant increases in associated
metabolic disorders such as diabetes, dyslipidemia, and high blood pressure. Together, these disorders constitute
metabolic syndrome, a clinically defined condition highly prevalent among African-Americans. Identifying epigenetic
alterations associated with metabolic syndrome may provide additional information regarding etiology beyond current
evidence from genome-wide association studies.
Methods: Data on metabolic syndrome and DNA methylation was assessed on 614 African-Americans from the
Hypertension Genetic Epidemiology Network (HyperGEN) study. Metabolic syndrome was defined using the joint
harmonized criteria, and DNA methylation was assessed using the Illumina HumanMethylation450K Bead Chip
assay on DNA extracted from buffy coat. Linear mixed effects regression models were used to examine the association
between CpG methylation at > 450,000 CpG sites and metabolic syndrome adjusted for study covariates. Replication using
DNA from a separate sample of 69 African-Americans, as well as meta-analysis combining both cohorts, was conducted.
Results: Two differentially methylated CpG sites in the IGF2BP1 gene on chromosome 17 (cg06638433; p value =
3.10 × 10− 7) and the ABCG1 gene on chromosome 21 (cg06500161; p value = 2.60 × 10− 8) were identified. Results
for the ABCG1 gene remained statistically significant in the replication dataset and meta-analysis.
Conclusion: Metabolic syndrome was consistently associated with increased methylation in the ABCG1 gene in
the discovery and replication datasets, a gene that encodes a protein in the ATP-binding cassette transporter family
and is involved in intra- and extra-cellular signaling and lipid transport.
Background
The prevalence of obesity among US adults has in-
creased steadily over the past few decades, and currently
over two thirds of US adults are either obese or over-
weight [1]. Excess adipose tissue is linked with chronic
inflammation, immune system activation, and oxidative
stress, as well as hypertension, dyslipidemia, and insulin
resistance. This cluster of inter-related conditions is de-
fined clinically as metabolic syndrome (MetS), and the
prevalence of this condition has increased concurrently
with obesity rates in the USA [2]. The link between
MetS and increased risk and mortality due to many
chronic diseases such as cardiovascular disease (CVD),
arthritis, chronic kidney disease, schizophrenia, and can-
cer [3–12] has been reported in published studies. More
recently, there has been renewed interest in better un-
derstanding the biological mechanisms underlying the
pathogenesis of MetS.
Epigenetic studies provide a unique lens for clarifying
molecular pathways through which lifestyle and environ-
mental factors such as diet and physical activity coupled
with individual genetic background interact to influence
health outcomes. Alterations in epigenetic patterns, such
as DNA methylation, which are modifiable, provide a
potential mechanism through which MetS and other en-
vironmental factors may influence gene expression and
ultimately increasing disease risk or mortality. Like other
chronic diseases, marked racial differences exist in the
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prevalence of MetS and its components [2], and the bio-
logical mechanisms underlying such disparities remain
unclear. Studies of DNA methylation alterations provide
an opportunity to systematically interrogate the epige-
nome to identify population-specific variation associated
with disease risk and health outcomes.
The goal of the present study is to examine DNA
methylation signatures measured across the genome asso-
ciated with MetS using DNA from African-American
adults included in the Hypertension Genetic Epidemiology
Network (HyperGEN) study, with replication in an inde-
pendent cohort of participants in the REasons for Geo-
graphic and Racial Differences in Stroke (REGARDS)
study. Results will enhance understanding of the patho-
physiology of this condition among African-Americans
and potentially lead to the development of novel bio-
markers or molecular targets for clinical studies.
Methods
Study population and baseline variables
The Hypertension Genetic Epidemiology Network
(HyperGEN) study is a cross-sectional, population-based
study of 1224 hypertensive African-American sibships
initially recruited between 1996 and 1999. The study
was later extended to other siblings and offspring of the
original sib-pair. Using stored samples, an ancillary epi-
genetic study was conducted among cohort participants
belonging to the highest and lowest quartiles (total N =
636) of left ventricular mass (LV mass). The family
structure of this HyperGEN epigenetic study population,
including the number of individuals per family, parent-
child, and sibling pairs, is presented in Additional file 1:
Table S1. Detailed lifestyle, biometric, and laboratory
measures were obtained in HyperGEN, including blood
pressure, medications, fasting blood glucose, triglycer-
ides, HDL cholesterol, height, weight, and waist circum-
ference. BMI was calculated using standard measures.
Metabolic syndrome
This was defined using the recently published joint har-
monized criteria [13]. The criteria defined MetS as hav-
ing three or more of the following components: (1)
elevated waist circumference (≥ 88 cm for women and ≥
102 cm for men), (2) elevated triglycerides (≥ 150 mg/
dL) or on treatment for dyslipidemia (statin and/or fibric
acid derivative), (3) reduced high-density lipoprotein
(HDL) cholesterol (< 40 mg/dL in men and < 50 mg/dL
in women) or on treatment for dyslipidemia (statin and/
or fibric acid derivative), (4) elevated blood pressure
(systolic ≥ 130 and/or diastolic ≥ 85 mmHg) or antihy-
pertensive drug treatment in a patient with a history of
hypertension), and (5) elevated fasting glucose (≥
100 mg/dL) or drug treatment for elevated glucose. Of
the 636 adults evaluated from the HyperGen cohort, 614
had methylation and MetS data for the basic model; an
additional 8 had missing covariate data, leaving 606 for
the fully adjusted model.
Epigenomic analysis
The Illumina HumanMethylation450 array was used to
analyze DNA extracted from buffy coat. These arrays
can measure DNA methylation at > 480,000 cytosine-
phosphate-guanine (CpG) sites. Briefly, 500 ng of buffy
coat DNA was hybridized to the Methyl450 array after
bisulfite conversion with EZ DNA kits (Zymo Research,
Irvine, CA) prior to standard Illumina amplification,
hybridization, and imaging steps. The resulting intensity
files were analyzed with Illumina’s GenomeStudio, which
generated beta (β) scores (i.e., the proportion of total sig-
nal from the methylation-specific probe or color chan-
nel) and “detection p values” (probability that the total
intensity for a given probe falls within the background
signal intensity). Quality control (QC) measures were
conducted by removing samples having more than 1% of
CpG sites with a detection p value > 0.05, removing CpG
sites having more than 5% of samples with a detection p
value > 0.01, and CpG sites with detection p value > 0.01
set as missing. After these QC filters, 484,366 CpG sites
were eligible for analysis. We normalized the β scores
using the Subset-quantile Within Array Normalization
(SWAN) method in minifi package to correct for differ-
ences between batches and the type I and type II assay
designs within a single 450K array [14]. Cell count pro-
portions (CD8 T lymphocytes, CD4 T lymphocytes, nat-
ural killer cells, B cells, and monocytes) were created
using the algorithm developed by Houseman, which pre-
dicts underlying cellular composition of each sample
from DNA methylation patterns [15].
Available SNP data
GWAS data from HyperGEN has been previously de-
scribed [16]. African-Americans were genotyped with the
Affymetrix Genome Wide Human SNP Array 6.0 Array
for 872,242 SNPs (median call rate = 99.97%). This SNP
set was used for imputation with ~ 3.01 million HapMap
SNPs (release 22, phasing data, “revised union” of CEU
and YRI populations) using MACH [17, 18]. The GWAS
data described was used to investigate cis-methylation
quantitative trait loci (cis-meQTL) in the region of the sta-
tistically significant CpG association findings. HyperGEN-
imputed GWAS data was also used to create principal
components for ancestry included in epigenetic associ-
ation models to adjust for subpopulation structure [19].
Statistical analysis
We determined the proportion of study participants
meeting the criteria for MetS and used chi-square tests
and t tests to examine differences in baseline socio-
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demographic variables. We fit linear mixed effects re-
gression models with the CpG β score (approximating %
DNA methylation at a CpG site) as the outcome, MetS
as the predictor, and adjusted for age, sex, center, first
four principal components (PCs) for ancestry (ancestry
PCs), estimated cell proportions, batch effects (array,
row, and column to account for residual batch effects
after normalization), and family structure as a random
effect (R kinship package (lmekin function)) [20]. In the
fully adjusted model, we additionally adjusted for smok-
ing and alcohol use. A sensitivity model for our statisti-
cally significant findings was further adjusted for high
versus low left ventricular mass. We corrected for
multiple comparisons using a Bonferroni correction for
0.05/460,000 tests setting alpha to 1.1 × 10− 7. Given that
Bonferroni correction tends to be conservative, we also
used FDR correction for multiple testing. We
constructed Manhattan plots to present results of our
epigenome-wide association analysis of MetS and used
mixed models to compare methylation of the top CpG
sites by MetS and component status adjusting for family
structure (R kinship package (lmekin function)) [20]. To
evaluate the DNA sequence contributions to methyla-
tion at the top CpG loci, we conducted cis-meQTL ana-
lyses by interrogating associations between all SNPs
within 20 kb of the CpG site via linear mixed models
with the CpG β score as the outcome, adjusted for age,
sex, study site, ancestry PCs, blood cell counts, and fa-
milial relationship. For the cis-meQTL analysis, we used
the Bonferroni correction for multiple testing as 0.05/
the number of SNPs within a 20-kb window. Subse-
quently, significant SNPs from cis-meQTL analysis were
tested for association with MetS via mixed linear models
with MetS as the outcome, adjusted for age, sex, study
site, ancestry PCs, and familial relationship. We also
conducted lookups of the significant MetS SNPs in the
catalog of genome-wide association studies (www.gwas
central.org) to evaluate evidence for association with car-
diometabolic traits in other populations.
Replication analysis
To assess whether similar findings are replicated in a
separate study population, we analyzed DNA methyla-
tion data obtained from genomic DNA samples of 100
African-American participants in the REasons for Geo-
graphic and Racial Differences in Stroke (REGARDS)
study also assayed on the Illumina HumanMethyla-
tion450 array. In the REGARDS study, blood pressure,
fasting blood glucose, triglycerides, HDL cholesterol,
and waist circumference were obtained by trained health
professionals during in-home visits at study baseline.
Details of the REGARDS study have been published pre-
viously [21]. In brief, REGARDS is a nationally represen-
tative sample of 32,239 adults ages 45 years and older
(45% males and 41% African-American) recruited be-
tween 2003 and 2007 and followed for incident stroke
and other related cardiovascular outcomes. MetS was
defined in REGARDS following the joint harmonized
criteria, and epigenomic analysis was conducted using
data from 69 participants with complete information for
both methylation and MetS. Linear models were used to
test the association between CpG site methylation and
MetS, adjusting for age, sex, four principal components
for ancestry, and cell count proportions in the basic
model and adding alcohol and smoking in a fully ad-
justed model. Statistically significant CpGs from the
HyperGEN discovery analyses were tested for replication
in REGARDS, and a Bonferroni correction was applied
(of 0.05/2 significant CpGs = 2.5 × 10− 2).
Meta-analysis
Top results from the HyperGEN and REGARDS studies
were meta-analyzed using random effects models imple-
mented in the METASOFT program based on the
method of Han and Eskin [22] to ensure validity in the
presence of effect heterogeneity.
Results
Among 614 African-American adults in the HyperGen
study (67% female), about half (51%) met the criteria for
MetS (Table 1). MetS+ participants were older on average
compared with MetS− participants, 52 ± 10 years and 46
± 11 years, respectively. Body weight (98.5 vs. 84.3 kg),
waist circumference (112.4 vs. 96.6 cm), and BMI (35.4 vs.
29.8) were significantly higher in MetS+ compared with
MetS− participants. In addition, MetS+ participants had
higher levels of triglycerides (125.5 vs. 77 mg/dL) and
LDL cholesterol (128 vs. 118.5 mg/dL), lower levels of
HDL cholesterol (46.9 vs. 58.8 mg/dL), and higher preva-
lence of hypertension (87 vs. 49%) compared with MetS−
participants. Among MetS+ participants, 51% had three of
the five components, 28% had four, and 20% had five, and
among MetS− participants, 17% had none of the MetS
components, 34% had one, and 49% had two.
Two differentially methylated CpG sites—one in the
IGF2BP1 gene on chromosome 17 (cg06638433) and the
other in the ABCG1 gene on chromosome 21
(cg06500161)—were identified in the HyperGEN study
in the basic (Fig. 1) and fully adjusted (Additional file 1:
Figure S1) models. In the basic model adjusting for age,
sex, cell count proportions, ancestry, and family relation-
ship, MetS was associated with increased methylation at
cg06500161 (β = 0.017, p value = 1.08 × 10− 8) and
cg06638433 (β = 0.01, p value = 2.05 × 10− 8) (Table 2).
After additionally adjusting for alcohol use and smoking,
the associations remained consistent and statistically
significant for cg06500161 (β = 0.02, p value = 2.60 × 10−
8) and closely approached statistical significance for
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cg06638433 (β = 0.01, p value = 3.10 × 10− 7). The results
were consistent, but no longer statistically significant, in
a sensitivity model additionally adjusted for left
ventricular mass (cg06500161: β = 0.02, p value = 2.22 ×
10− 7; cg06638433: β = 0.01, p value = 2.19 × 107). The
LVM adjusted results were similar after the FDR
correction (adjusted p value = 0.054 for both cg06500161
and cg06638433). Mean DNA methylation level at each
of the two CpG sites was significantly higher among
HyperGEN participants meeting the criteria for an
individual MetS component as well as overall for MetS
status (Additional file 1: Figure S2).
Both cg06500161 and cg06638433 were examined for
association with MetS in the REGARDS cohort.
REGARDS participants with relevant data were overall 59.
5 ± 4.5 years of age and 47.8% female (see Additional file 1:
Table S2 for a description of the replication cohort by
MetS status). Similar to HyperGEN, we observed
increased DNA methylation levels at cg06500161 in both
the basic (β = 0.029, p value = 0.001) and fully adjusted (β
= 0.032, p value 4.7 × 10− 4) models in REGARDS. In
meta-analysis of the combined HyperGEN and REGARDS
cohorts, the association for cg06500161 remained consist-
ent (meta-analysis for fully adjusted model: p value = 2.
15 × 10− 10; Table 2). IGF2BP1 cg06638433 was not
associated with MetS in REGARDS, and the effect was in
the opposite direction (Table 2).
In the cis-meQTL analysis, 16 SNPs were significantly
associated with methylation at the cg06500161 locus
upon Bonferroni correction for multiple testing (3.2 ×
10− 4 = 0.05/154 SNPs within 20 kb of cg06500161),
reflecting potential contributions to the methylation
signal from underlying common DNA sequence variants
(Fig. 2). Among those 16 SNPs, 7 were in turn
associated with MetS (p < 0.05) with the top SNP
association signals being for rs17114493 and rs4547619
Fig. 1 Epigenome-wide association for metabolic syndrome among African-Americans in HyperGEN study (N = 614). Basic model includes age,
sex, center, first four principal components, five estimated cell proportions, batch effect, and family structure
Table 1 Baseline characteristics of HyperGen study participants
MetS+
(N = 284)
MetS−
(N = 330)
p value*
Age† 52.0 ± 10.0 46.0 ± 11.0 < 0.0001
High WC/obesity
WC (cm)† 112.4 ± 16.6 96.6 ± 16.9 < 0.0001
BMI† 35.4 ± 8.1 29.8 ± 7.4 < 0.0001
Elevated triglycerides
Triglycerides (mg/dL)§ 125.5 ± 83.5 77.0 ± 42.8 < 0.0001
Reduced HDL cholesterol
HDL cholesterol (mg/dL)† 46.9 ± 12.5 58.8 ± 15.5 < 0.0001
Elevated blood pressure
DBP (mmHg)† 75.3 ± 11.8 75.5 ± 13.3 0.8
SBP (mmHg)† 136 ± 22.8 127.6 ± 23.7 < 0.0001
Hypertension (%) 86.6 48.9 < 0.0001
Elevated fasting glucose
Fasting glucose (mg/dL)† 133.8 ± 69.9 94.2 ± 31.2 < 0.0001
Metabolic components** (%)
0 0 17.3
1 0 33.9
2 0 48.8
3 51.4 0
4 28.2 0
5 20.4 0
BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein,
DBP diastolic blood pressure, SBP systolic blood pressure
†Presented as mean (standard deviation) for normal continuous characteristics
§Presented as median (interquartile range) for non-parametric
continuous characteristics
*Significance determined using chi-square test for categorical, t test for continuous,
or kruskal.test test for non-parametric continuous variables
**Metabolic components are high waist circumference (WC), elevated triglycerides,
reduced HDL cholesterol, elevated blood pressure, and elevated fasting glucose
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(Table 3). None of the 7 SNPs had previously been
identified in GWAS of MetS or other metabolic traits.
Those SNPs were associated with decreased methylation
at cg06500161 yet increased MetS risk. In our primary
analysis, MetS was associated with increased
methylation at cg06500161. These results suggest these
SNPs are not associated with MetS through this
methylation site. Data from ENCODE shows that
cg06500161 is a downstream of a predicted promoter
region (Fig. 3).
Discussion
In a sample of African-American adults with a 51%
prevalence of MetS, we observed that MetS was associ-
ated with increased methylation on the cg06500161
locus in the ABCG1 gene. This finding was successfully
replicated in an independent sample of African-
American adults in the REGARDS cohort, and meta-
analysis of data from the two studies strengthened the
association of the CpG with MetS. Methylation at
cg06500161 (within a CpG island shore) [23] was associ-
ated with each MetS component suggesting this locus
has pleiotropic effects. Evaluation of the region in EN-
CODE revealed the CpG is in a strong regulatory region
which suggests that differential methylation at this locus
could impact gene expression. An analysis of common
SNPs in the region did not confirm SNPs influence on
the relationship between the CpG and MetS.
This study is one of the firsts to report a potential epi-
genetic mechanism associated with a highly prevalent
condition among African-American adults. Other stud-
ies have identified loci associated with MetS traits [24,
25], including central obesity, insulin responsiveness,
and type 2 diabetes [26, 27], as well as lipid profiles in
diverse populations [28, 29]. Das et al. identified de-
creased methylation at two loci of the CPT1A gene, in-
volved in fatty acid oxidation, associated with MetS
status in a Caucasian population, which corroborates
findings by a prior study observing differential methyla-
tion at the same loci associated with triglycerides and
very low-density lipoprotein cholesterol levels [25].
Table 2 Top CpG methylation sites associated with metabolic syndrome status in HyperGEN discovery and REGARDS replication and
meta-analysis in basic and adjusted models
Study Model CpG Chr Gene Location β (SE) p value
Discovery set
HyperGEN (N = 614 (basic) and 606 (fully adjusted)) Basic cg06500161 21 ABCG1 43656587 0.017 (2.05 × 10− 3) 1.08 × 10−8
cg06638433 17 IGF2BP1 47075175 0.01 (1.90 × 10−3) 2.05 × 10−8
Fully adjusted cg06500161 21 ABCG1 43656587 0.018 (3.20 × 10−3) 2.60 × 10−8
cg06638433 17 IGF2BP1 47075175 0.01 (2.01 × 10−3) 3.10 × 10−7
Replication set
REGARDS (N = 69) Basic cg06500161 21 ABCG1 43656587 0.029 (8.94 × 10−3) 0.001
cg06638433 17 IGF2BP1 47075175 − 0.024 (0.012) 0.05
Fully adjusted cg06500161 21 ABCG1 43656587 0.032 (9.0 × 10−3) 4.7 × 10−4
cg06638433 17 IGF2BP1 47075175 − 0.026 (0.012) 0.035
Meta-analysis
HyperGEN and REGARDS Basic cg06500161 21 ABCG1 43656587 N/A 1.54 × 10−10
Fully adjusted cg06500161 21 ABCG1 43656587 N/A 2.15 × 10− 10
Basic cg06638433 17 IGF2BP1 47075175 N/A 1.29 × 10−7
Full adjusted cg06638433 17 IGF2BP1 47075175 N/A 1.55 × 10−6
Basic models refer to linear mixed models with metabolic syndrome as a predictor and CpG β score as the outcome, adjusted for age, sex, center, first four principal
components, and five estimated cell proportions. Full adjusted models were additionally adjusted for smoking and alcohol use. Meta-analysis p values are from Han and
Eskin [22] random effects models
Fig. 2 Associations between 154 ABCG1 genetic variants within
20 kb (upstream and downstream) of the cg06500161 chromosome
21 locus and its methylation status (cis-meQTL). SNPs above the dashed
line have p value for association > 0.05/154
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Methylation of the cg18181703 locus in the SOCS3 gene,
involved in leptin and insulin signaling, was also identi-
fied in a separate study, inversely correlated with BMI,
triglycerides, and MetS but positively correlated with
HDL-c levels [24]. Relevant to our findings, Yoon et al.
independently identified ABCG1 (cg06500161) as being
associated with MetS (in a Caucasian Veteran popula-
tion) using an Iterative Sure Independence Screening
analysis approach [30]. ABCG1 cg06500161 has also
been reported to be associated with fasting insulin (in
Caucasian non-diabetic adults) [26], blood lipids, and
adiposity traits [29, 31]. Additionally, our results are con-
sistent with a recent study of epigenetic determinants of
type 2 diabetes in Mexican-Americans, showing differen-
tial DNA methylation levels at ABCG1 [27]. Taken to-
gether, these studies suggest that epigenetic variations are
Table 3 The results of cis-methylation quantitative trait loci for cg06500161 in ABCG1 gene
CpG SNP Effect allele β SNP-CpG SE SNP-CpG p value of SNP-CpG OR SNP-MetS SE SNP-MetS p value of SNP-MetS
cg06500161 rs9978671 C − 0.0203 0.0030 9.98 × 10−10 1.13 0.07 0.08
cg06500161 rs17114493 T − 0.0264 0.0050 7.20 × 10−7 1.22 0.07 4.30 × 10−3
cg06500161 rs4547619 C − 0.0264 0.0050 7.20 × 10−7 1.22 0.07 4.30 × 10−3
cg06500161 rs225440 C 0.0123 0.0025 2.96 × 10−6 0.91 0.07 0.19
cg06500161 rs225448 T 0.0123 0.0025 4.16 × 10−6 0.88 0.07 0.06
cg06500161 rs2839475 A − 0.0220 0.0046 5.38 × 10−6 1.22 0.07 5.94 × 10−3
cg06500161 rs1824010 C −0.0222 0.0048 9.93 × 10−6 1.20 0.07 8.98 × 10−3
cg06500161 rs8130198 A − 0.0222 0.0048 9.93 × 10−6 1.20 0.07 8.98 × 10−3
cg06500161 rs8134682 T − 0.0222 0.0048 9.93 × 10−6 1.20 0.07 8.98 × 10−3
cg06500161 rs8129752 A − 0.0225 0.0049 1.27 × 10−5 1.21 0.07 6.47 × 10−3
cg06500161 rs7283699 G − 0.0131 0.0029 1.51 × 10−5 1.13 0.07 0.08
cg06500161 rs9974658 G − 0.0131 0.0031 4.65 × 10− 5 1.11 0.07 0.17
cg06500161 rs915847 G 0.0118 0.0028 4.97 × 10−5 0.99 0.07 0.84
cg06500161 rs12329683 T − 0.0130 0.0031 6.80 × 10−5 1.09 0.07 0.22
cg06500161 rs9982196 T − 0.0120 0.0029 7.61 × 10−5 1.12 0.07 0.13
cg06500161 rs9978842 C − 0.0144 0.0036 1.03 × 10−4 1.12 0.07 0.13
Linear mixed models were used for SNP-CpG association with CpG β score as the outcome adjusted for age, sex, study site, ancestry principal components, cell
counts, and familial relationship. Logistic mixed models were used for SNP-MetS association with MetS as the outcome adjusted for age, sex, center, first four PCs,
and familial relationship
MetS metabolic syndrome
Fig. 3 ENCODE plot with MetS signal of cg06500161. Genome segmentations from ENCODE color coding: bright red, predicted promoter region
including transcription start site (TSS); light red, predicted promoter flanking region; orange, predicted enhancer; yellow, predicted weak enhancer
or open chromatin cis-regulatory element; blue, CTCF (CCCTC-binding factor)-enriched element; dark green, predicted transcribed region; and gray,
predicted low activity region
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strongly associated with MetS and its components and
that ABCG1 has been a consistent finding across diverse
ethnic populations, strengthening the credibility of this
gene’s relationship with metabolic traits.
ABCG1 encodes for a protein included in the ATP-
binding cassette (ABC) transporters superfamily, in-
volved in the transport of molecules across extra- and
intra-cellular membranes. ABCG1 in particular plays an
important role in macrophage cholesterol and phospho-
lipid transport, and the regulation of cellular lipid
homeostasis. Downregulation of ABCG1 and ABCA1 has
been associated with reduced cholesterol efflux and has
been shown to increase the risk of atherosclerosis [32].
Other studies have reported an association between
ABCG1 methylation and coronary artery disease [33,
34], and several studies report an association between
liver X receptor, an inducer of ABC transporter gene ex-
pression, and cholesterol efflux which results in the in-
hibition of cell proliferation and stimulation of apoptosis
in cancer [35, 36]. This evidence, taken together with
the observation that alterations in the ABCG1 gene were
observed in 40% of invasive breast cancer tumors in the
Cancer Genome Atlas [37, 38], provides a potential epi-
genetic link between MetS and chronic diseases includ-
ing cancer that deserves further study. The higher
methylation levels of ABCG1 observed with MetS pro-
vide evidence for potential therapeutic targets that may
be useful in drug development, and/or prevention of
chronic diseases including CVD and cancer.
There are several limitations inherent in this study.
First, HyperGen was a cross-sectional study of African-
American adults, and this study design limits our ability
to infer causality between MetS and DNA methylation.
Prospective studies will be needed to definitively deter-
mine whether increased methylation of ABCG1 is a con-
sequence or cause of MetS. At least one Mendelian
randomization study in Caucasian populations reported
that lipids change methylation at cg06500161 suggesting
the potential for a feedback loop mechanism that war-
rants further investigation [39]. In fact, if MetS affects
methylation at ABCG1, this could help explain why our
results did not suggest cis-meQTL SNPs influence the
CpG-MetS relationship. Although we were able to iden-
tify significantly altered methylation on an ABCG1 locus
in relation to MetS among African-Americans that is
consistent with epigenetic studies of metabolic traits in
other ethnicities, improved understanding of racial dif-
ferences in the biological mechanisms leading to signifi-
cantly higher prevalence of MetS and components such
as type 2 diabetes in African-Americans relative to other
racial groups will require a larger study with adequate
representation of multiple racial groups. DNA methyla-
tion was measured on stored and frozen buffy coat sam-
ples, which may have been altered during the freezing
and thawing process; however, buffy coat samples are
widely used for methylation analysis due to the high
concentration of DNA. A major strength of the study is
the use of epigenome-wide methylation analysis using a
wide panel of CpG markers on understudied African-
Americans and replication in a separate independent
sample of African-American participants.
Conclusion
In conclusion, MetS in African-American adults was as-
sociated with increased methylation at the cg06500161
locus in the ABCG1 gene, located in a highly conserved
regulatory region of the genome. ABCG1, involved in
cholesterol and phospholipid transport, has been associ-
ated with MetS and component traits in other studies.
The high prevalence of MetS among African-Americans
and the consistent associations between MetS and many
chronic diseases such as cancer highlight the need for
future prospective confirmatory studies that may inform
clinical strategies and interventions.
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